Skip to main content

16-12-2012 | Breast cancer | Article

18FDG–PET–CT improves breast cancer staging


Free full text

medwireNews: A prospective study has shown fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET-CT) to be a powerful tool for the detection of nodal and distant metastatic disease in patients with breast cancer.

When applied to 254 patients with stage II or III disease diagnosed by clinical examination, magnetic resonance imaging, or ultrasound, 18FDG-PET-CT findings led to a change of American Joint Committee on Cancer stage in 30.3% of patients, report David Groheux (Hôpital Saint-Louis, Paris, France) and co-authors.

18FDG-PET-CT had the greatest impact on patients with the most advanced disease, leading to a stage change in 16.1% of stage IIB patients, 31.7% of stage IIIA patients, 51.4% of stage IIIB patients, and 47.1% of stage IIIC patients.

"It is hoped that the information provided at initial staging might lead to better management of these patients who account for the largest mortality rate from breast cancer," say Groheux et al.

As 18FDG-PET-CT findings resulted in a stage change in just 4.5% of stage IIA patients, however, the team believes that the imaging technique may be "justified" only for patients with stage IIB disease or above.

Stage modification was prompted by the detection of previously unsuspected disease in the infraclavicular, supraclavicular, or internal mammary nodes, or distant metastases by 18FDG-PET-CT.

Following up patients with clinical IIB or greater disease, 3-year disease-specific survival was significantly shorter for the patients with distant metastases on 18FDG-PET-CT compared with those who had no evidence of distant metastases, at 57% versus 88%.

In multivariate analysis, distant metastatic disease on 18FDG-PET-CT and a triple-negative breast cancer phenotype were the only significant prognostic factors for disease-specific survival. The relative risk for death for M1 versus M0 patients was 26.60, while the relative risk for triple-negative phenotype versus other phenotypes was 18.58.

"The remarkable progression in the yield of 18FDG-PET-CT with advancing clinical stage and the correlation between PET-CT findings and prognosis are strong arguments that the overwhelming majority of patients classified as M+ on the basis of 18FDG-PET-CT have true-positive metastases," the researchers say.

Nevertheless, they emphasize that as their findings were in a single institution, the research must be repeated in other settings.

medwireNews ( is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2012

By Lynda Williams, Senior medwireNews Reporter

Related topics